USP39

Ubiquitin carboxyl-terminal hydrolase 39 · Q53GS9 · USP39 on Sugi Atlas →

0 patent compounds predicted against USP39, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to USP39 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma PHASE2WITHDRAWN
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma PHASE2SUSPENDED
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study PHASE2WITHDRAWN
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Diagnostic Potential of UCHL1 in Acute Decompensated Heart Failure nanCOMPLETED
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma nanCOMPLETED
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Prognostic Biomarkers in Tumor Tissue Samples From Young Patients With Neuroblastoma nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome nanRECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit nanCOMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
The PREServation of MUScle Function in Critically Ill Patients (PRESMUS) nanUNKNOWN
Relationship Between Nutritional State and Respiratory Muscle Weakness in Adult Patients With Bronchietasis nanUNKNOWN
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a USP39 binder may also engage these)

ProteinNameSimilarity
Q5R761 1.000 Q5R761 →
Q3TIX9 1.000 Q3TIX9 →
Q5F450 0.948 Q5F450 →
Q9WUP7 0.947 Q9WUP7 →
Q9ERA0 0.945 Q9ERA0 →
P60762 0.944 P60762 →
Q9XSJ0 0.943 Q9XSJ0 →
MORF4L1 Mortality factor 4-like protein 1 0.942 landscape →
Q06AT3 0.941 Q06AT3 →
Q12800 0.941 Q12800 →
DHX9 ATP-dependent RNA helicase A 0.940 landscape →
Q5R874 0.940 Q5R874 →
Q5NVP9 0.940 Q5NVP9 →
UCHL5 Ubiquitin carboxyl-terminal hydrolase isozyme L5 0.940 landscape →
Q6AYU1 0.940 Q6AYU1 →
RPTOR Regulatory-associated protein of mTOR 0.939 landscape →
Q8K4Q0 0.939 Q8K4Q0 →
Q7Z6J6 0.938 Q7Z6J6 →
Q28141 0.938 Q28141 →
Q6NZH6 0.938 Q6NZH6 →
Q7T2U9 0.937 Q7T2U9 →
Q6P5H6 0.937 Q6P5H6 →
GPS1 COP9 signalosome complex subunit 1 0.936 landscape →
Q96L92 0.936 Q96L92 →
E1C1R4 0.936 E1C1R4 →
AP2A2 AP-2 complex subunit alpha-2 0.935 landscape →
A2A432 0.935 A2A432 →
P17427 0.935 P17427 →
P18484 0.935 P18484 →
Q6NRT5 0.935 Q6NRT5 →